Seeking Domestic Pharmaceuticals

The Department of Veterans Affairs Veterans Health Administration (VA VHA) is conducting a Request for Information (RFI) to identify domestic pharmaceutical manufacturers capable of producing seven specific pharmaceutical products, including Trazodone HCL, Sertraline HCL, Divalproex, Zolpidem Tartrate, Hydroxychloroquine Sulfate, Errin, and Camphor Menthol Methyl Salicylate Patches. The RFI targets manufacturers who can supply an estimated seven VA facilities, with requirements encompassing full production responsibilities including labor, materials, quality assurance, and compliant delivery. Manufacturers must submit a comprehensive capability statement by April 3, 2025, at 16:30 CDT to Josie Linaweaver via email, with submissions required to include detailed company information, domestically manufactured pharmaceutical specifics, authorized distributors, prescription costs, stock availability history, and applicable contract schedule numbers. The solicitation falls under NAICS code 325412 with a business size standard of 1,250 employees, and seeks responses from various socioeconomic categories including Service-Disabled Veteran-Owned Small Businesses (SDVOSB), Veteran-Owned Small Businesses (VOSB), and 8(a) businesses. This market research initiative is designed to explore potential domestic pharmaceutical manufacturing capabilities and does not guarantee a future contract award.

The RFI does not include a specific set-aside designation, indicating openness to a broad range of pharmaceutical manufacturers. While no incumbent contractors are mentioned, the solicitation emphasizes a preference for domestic production capabilities. The document does not specify precise award values or budget ranges, though it implies potential supply contracts for seven VA facilities. The targeted pharmaceutical products suggest a focus on mental health, sleep, and pain management medications, with manufacturers expected to demonstrate consistent stock availability and competitive pricing. The PSC category of 6505 (Drugs and Biologicals) further clarifies the procurement's pharmaceutical focus, and the April 3, 2025 response deadline suggests the VA is actively researching market capabilities for near-term procurement considerations. Interested manufacturers are encouraged to provide comprehensive information to demonstrate their domestic production capabilities and compliance with federal healthcare supply requirements.